¼¼°èÀÇ »çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº °ü¸® ½ÃÀå º¸°í¼­(2025³â)
Cytokine Release Syndrome Management Global Market Report 2025
»óǰÄÚµå : 1760513
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

»çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº °ü¸® ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö 6.5%ÀÇ CAGR·Î 306¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀÇ ¿øµ¿·ÂÀº Áø´Ü µµ±¸ ¹× Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Á¤ºÎ º¸Á¶±Ý Áõ°¡, È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °í·ÉÈ­, °ø°ø ¹× ¹Î°£ ±â°üÀÇ ÀÌ´Ï¼ÅÆ¼ºê È®´ë µîÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÃÖ¼Òħ½ÀÀû À¯¹æ »ý°Ë ÀåºñÀÇ °³¹ß, Àü·«Àû ÆÄÆ®³Ê½Ê ¹× Á¦ÈÞ, ÀçÅà Ç×»ýÁ¦ ÁÖÀÔ ¼­ºñ½º, »õ·Î¿î ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ÃâÇö, °¨¿° ÃßÀûÀ» À§ÇÑ ÀüÀÚ ÀÇ·á ±â·ÏÀÇ ÅëÇÕ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

Ç¥Àû Ä¡·áÁ¦ÀÇ »ç¿ë Áõ°¡´Â ÇâÈÄ ¸î ³â µ¿¾È »çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç¥Àû Ä¡·áÁ¦´Â Á¾¾ç ¹ß»ý¿¡ °ü¿©ÇÏ´Â ºÐÀÚ °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ¾ÏÀÇ ¼ºÀå°ú È®»êÀ» ¸·±â À§ÇØ Æ¯º°È÷ °í¾ÈµÈ Ä¡·á¹ýÀÔ´Ï´Ù. Ç¥Àû Ä¡·áÁ¦ÀÇ Áõ°¡´Â ÁÖ·Î °Ç°­ÇÑ ¼¼Æ÷¿¡ ´ëÇÑ ÇÇÇØ¸¦ ÃÖ¼ÒÈ­Çϸ鼭 ¾Ï¼¼Æ÷¸¦ Á¤È®ÇÏ°Ô Ç¥ÀûÈ­ÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ±âÀÎÇϸç, ±âÁ¸ Ä¡·á¹ý¿¡ ºñÇØ Ä¡·á È¿°ú´Â Çâ»óµÇ°í ºÎÀÛ¿ëÀº °¨¼ÒÇÏ´Â µî CRSÀÇ °ü¸®´Â CAR-T ¼¼Æ÷ Ä¡·áÁ¦, ¸é¿ª°ü¹®¾ïÁ¦Á¦ µî Ä¡·áÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ³ôÀ̱â À§ÇØ ½É°¢ÇÑ ¿°Áõ ¹ÝÀÀÀ» Á¶ÀýÇÏ¿© Ç¥Àû Ä¡·á¸¦ ÃÖÀûÈ­ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù ¹Ì±¹ À¯ÀüÀÚ ¹× ¼¼Æ÷ Ä¡·áÇÐȸ(American Society of Gene and Cell Therapy)´Â 2023³â 4ºÐ±â¿¡ ÀÓ»ó 3»ó ½ÃÇè ÁßÀÎ À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ ¼ö°¡ 10% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó Ç¥Àû Ä¡·áÁ¦ÀÇ »ç¿ë È®´ë°¡ »çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

»çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº °ü¸® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ¼÷ÁÖ ÁöÇ⼺ ÀúºÐÀÚ ¾à¹°°ú °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, °¨¿°À̳ª ¾Ï°ú ½Î¿ì´Â ½ÅüÀÇ ´É·ÂÀ» ¼Õ»ó½ÃŰÁö ¾Ê°í ¸é¿ª ¹ÝÀÀÀ» Á¶ÀýÇÏ¿© »çÀÌÅäÄ«ÀÎ ÆøÇ³ÀÇ ½É°¢¼ºÀ» °¨¼Ò½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ¼÷ÁÖ ÁöÇ⼺ ÀúºÐÀÚ ÀǾàǰÀº ¼÷ÁÖÀÇ ¸é¿ª ½ÅÈ£Àü´Þ °æ·Î¸¦ Ÿ°ÙÀ¸·Î ¼³°èµÈ ÀúºÐÀÚ È­ÇÕ¹°·Î, °úµµÇÑ »çÀÌÅäÄ«ÀÎ »ý¼ºÀ» ¾ïÁ¦ÇÏ°í ¸é¿ªÃ¼°èÀÇ °úÀ× È°¼ºÈ­¸¦ ¹æÁöÇÏ¿© CRS °ü¸®¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 4¿ù ¹Ì±¹ »ý¸í°øÇÐ ±â¾÷ »çÀÌÅä¿¡ÀÌÀüÆ®(CytoAgents Inc.)´Â CAR-T ¼¼Æ÷ Ä¡·á ȯÀÚÀÇ CRS ¿¹¹æ ¹× Ä¡·á¸¦ À§ÇÑ ¼÷ÁÖ ÁöÇ⼺ ÀúºÐÀÚ ¾à¹° CTO1681ÀÇ 1b/2a»ó ÀÓ»ó 1b/2a»ó ½ÃÇè¿¡¼­ ù ¹øÂ° ¿ë·® Áõ·® ÄÚȣƮ°¡ ¼º°øÀûÀ¸·Î Á¾·áµÇ¾ú´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÀÓ»ó½ÃÇè¿¡¼­ CTO1681Àº ¾çÈ£ÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» º¸¿´À¸¸ç, ¿ë·® Á¦ÇÑ µ¶¼ºÀ̳ª CAR T ¼¼Æ÷ÀÇ È¿´ÉÀ» ÀúÇØÇÏÁö ¾Ê¾Ò½À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇèÀº CTO1681ÀÇ ¾ÈÀü¼º, ³»¾à¼º, ¿¹ºñ À¯È¿¼ºÀ» Æò°¡ÇÏ°í ±ÇÀå 2»ó ¿ë·®À» °áÁ¤Çϱâ À§ÇÑ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Cytokine release syndrome (CRS) management involves medical strategies to control the excessive immune response caused by an overproduction of cytokines, often seen in conditions such as CAR-T cell therapy or certain infections. The management approach includes medications such as corticosteroids and cytokine inhibitors, supportive care, and, in some cases, intensive monitoring to prevent severe complications. Effective management is critical for reducing the risk of severe organ damage and improving patient outcomes.

The primary treatment options for CRS include monoclonal antibodies, corticosteroids, intravenous immunoglobulin (IVIG), targeted therapy, supportive care, and other treatments. Monoclonal antibodies are laboratory-engineered molecules that target specific cytokines or their receptors to regulate immune activity and manage CRS. These antibodies are used for a range of conditions, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, hematopoietic stem cell transplantation (HSCT), autoimmune diseases, infections, and others. They can be administered intravenously (IV), subcutaneously (SC), orally, intramuscularly (IM), intrathecally, or by other methods. These treatments are provided through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, research institutions, and others.

The cytokine release syndrome management market research report is one of a series of new reports from The Business Research Company that provides cytokine release syndrome management market statistics, including cytokine release syndrome management industry global market size, regional shares, competitors with a cytokine release syndrome management market share, cytokine release syndrome management market segments, market trends, and opportunities, and any further data you may need to thrive in the cytokine release syndrome management industry. This cytokine release syndrome management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $22.32 billion in 2024 to $23.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth during the historic period can be attributed to rising healthcare expenditures, increasing awareness, changing lifestyles, higher disposable incomes, the adoption of personalized medicine approaches, and greater use of targeted therapies.

The cytokine release syndrome management market size is expected to see strong growth in the next few years. It will grow to $30.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. Growth in the forecast period is expected to be driven by increased demand for diagnostic tools and treatments, growing government funding, a rising need for effective therapies, an aging population, and expanding initiatives by both public and private organizations. Key trends in the forecast period include the development of minimally invasive breast biopsy devices, strategic partnerships and collaborations, home-based antibiotic infusion services, the emergence of novel drug delivery systems, and the integration of electronic health records for infection tracking.

The increasing use of targeted therapies is expected to drive the growth of the cytokine release syndrome management market in the coming years. Targeted therapies are treatments specifically designed to block the growth and spread of cancer by targeting molecular pathways involved in tumor development. The rise in targeted therapies is mainly attributed to their ability to precisely target cancer cells while minimizing harm to healthy cells, which improves treatment efficacy and reduces side effects compared to traditional therapies. CRS management plays a vital role in optimizing targeted therapies by controlling severe inflammatory responses, thus enhancing the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For example, in January 2024, the American Society of Gene and Cell Therapy reported that in the fourth quarter of 2023, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first rise of this kind since the third quarter of 2022. Therefore, the growing use of targeted therapies is fueling the growth of the cytokine release syndrome management market.

Major companies in the cytokine release syndrome management market are focusing on developing innovative therapies, such as host-directed small molecule drugs, which aim to modulate the immune response and reduce the severity of cytokine storms without compromising the body's ability to fight infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to target immune signaling pathways in the host, helping manage CRS by suppressing excessive cytokine production and preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, announced the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug aimed at preventing and treating CRS in patients receiving CAR T-cell therapy. The investigational therapy showed a favorable safety profile, with no dose-limiting toxicities or disruption to CAR T-cell efficacy. The ongoing trial is designed to assess the safety, tolerability, and preliminary efficacy of CTO1681 and determine the recommended Phase 2 dose.

In March 2024, Merck & Co., Inc., a US-based biopharmaceutical company, acquired Harpoon Therapeutics for $680 million to strengthen its oncology pipeline with innovative T-cell engager therapies. This acquisition integrates Harpoon's T-cell engager technology and lead candidate, MK-6070, currently in a Phase 1/2 trial for advanced cancers, enhancing Merck's immuno-oncology capabilities and expanding its portfolio of next-generation cancer therapies. Harpoon Therapeutics, a clinical-stage biopharmaceutical company, specializes in T-cell engagers for cancer treatment, focusing on its TriTAC-XR platform to reduce CRS and improve treatment efficacy.

Major players in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., and Humanigen Inc.

North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cytokine release syndrome management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cytokine release syndrome management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cytokine release syndrome management market consists of revenues earned by entities by providing services such as diagnostic testing, immunosuppressive therapy, supportive care, clinical trial services, and post-treatment monitoring to manage and treat patients affected by CRS. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome management market also includes sales of tocilizumab (actemra), siltuximab (sylvant), dexamethasone, ruxolitinib (jakafi), and ivig (intravenous immunoglobulin). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cytokine Release Syndrome Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cytokine release syndrome management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cytokine release syndrome management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cytokine release syndrome management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Cytokine Release Syndrome Management Market Characteristics

3. Cytokine Release Syndrome Management Market Trends And Strategies

4. Cytokine Release Syndrome Management Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cytokine Release Syndrome Management Growth Analysis And Strategic Analysis Framework

6. Cytokine Release Syndrome Management Market Segmentation

7. Cytokine Release Syndrome Management Market Regional And Country Analysis

8. Asia-Pacific Cytokine Release Syndrome Management Market

9. China Cytokine Release Syndrome Management Market

10. India Cytokine Release Syndrome Management Market

11. Japan Cytokine Release Syndrome Management Market

12. Australia Cytokine Release Syndrome Management Market

13. Indonesia Cytokine Release Syndrome Management Market

14. South Korea Cytokine Release Syndrome Management Market

15. Western Europe Cytokine Release Syndrome Management Market

16. UK Cytokine Release Syndrome Management Market

17. Germany Cytokine Release Syndrome Management Market

18. France Cytokine Release Syndrome Management Market

19. Italy Cytokine Release Syndrome Management Market

20. Spain Cytokine Release Syndrome Management Market

21. Eastern Europe Cytokine Release Syndrome Management Market

22. Russia Cytokine Release Syndrome Management Market

23. North America Cytokine Release Syndrome Management Market

24. USA Cytokine Release Syndrome Management Market

25. Canada Cytokine Release Syndrome Management Market

26. South America Cytokine Release Syndrome Management Market

27. Brazil Cytokine Release Syndrome Management Market

28. Middle East Cytokine Release Syndrome Management Market

29. Africa Cytokine Release Syndrome Management Market

30. Cytokine Release Syndrome Management Market Competitive Landscape And Company Profiles

31. Cytokine Release Syndrome Management Market Other Major And Innovative Companies

32. Global Cytokine Release Syndrome Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cytokine Release Syndrome Management Market

34. Recent Developments In The Cytokine Release Syndrome Management Market

35. Cytokine Release Syndrome Management Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â